Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study

Fabrizio Stocchi, Laura Vacca, Stefano Ruggieri, C. Warren Olanow

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Background: Levodopa-related motor complications can be an important source of disability for patients with advanced Parkinson disease. Current evidence suggests that these motor complications are related to the relatively short half-life of levodopa and its potential to induce pulsatile stimulation of striatal dopamine receptors. Motor complications can be diminished with a continuous infusion of levodopa. Objective: To investigate the specific pharmacokinetic changes associated with the benefits of levodopa infusion. Design: We performed an open-label study in 6 patients with Parkinson disease who experienced severe motor complications while receiving standard oral formulations of levodopa/carbidopa. Patients were subsequently treated for 6 months with continuous daytime intraintestinal infusions of levodopa methyl ester. Levodopa pharmacokinetic studies were performed at baseline and 6 months in 3 of these patients. Results: Compared with treatment with intermittent doses of a standard oral formulation of levodopa, continuous infusion provided significant improvement in both "off periods" and dyskinesia. Results of plasma pharmacokinetic studies demonstrated that compared with oral administration, continuous levodopa infusion was associated with a significant increase in the levodopa area under the curve and avoided the low plasma trough levels seen with oral drug administration. Conclusions: This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD. Pharmacokinetic studies demonstrate that reduced motor complications are associated with avoiding low plasma levodopa trough levels and are not adversely affected by relatively high plasma levodopa concentrations. We propose that if levodopa/ carbidopa could be administered orally in a manner that mirrors the pharmacokinetic pattern of the infusion, it might lead to a similar reduction in motor complications.

Original languageEnglish
Pages (from-to)905-910
Number of pages6
JournalArchives of Neurology
Volume62
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Levodopa
Parkinson Disease
Pharmacokinetics
Oral Administration
Clinical Studies
Parkinson's Disease
Complications
Corpus Striatum
Drug Compounding
Dyskinesias
Dopamine Receptors
Plasma
Area Under Curve
Half-Life

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease : A clinical and pharmacokinetic study. / Stocchi, Fabrizio; Vacca, Laura; Ruggieri, Stefano; Olanow, C. Warren.

In: Archives of Neurology, Vol. 62, No. 6, 06.2005, p. 905-910.

Research output: Contribution to journalArticle

@article{7cd4d3ad965b46888578089ced0f6c29,
title = "Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study",
abstract = "Background: Levodopa-related motor complications can be an important source of disability for patients with advanced Parkinson disease. Current evidence suggests that these motor complications are related to the relatively short half-life of levodopa and its potential to induce pulsatile stimulation of striatal dopamine receptors. Motor complications can be diminished with a continuous infusion of levodopa. Objective: To investigate the specific pharmacokinetic changes associated with the benefits of levodopa infusion. Design: We performed an open-label study in 6 patients with Parkinson disease who experienced severe motor complications while receiving standard oral formulations of levodopa/carbidopa. Patients were subsequently treated for 6 months with continuous daytime intraintestinal infusions of levodopa methyl ester. Levodopa pharmacokinetic studies were performed at baseline and 6 months in 3 of these patients. Results: Compared with treatment with intermittent doses of a standard oral formulation of levodopa, continuous infusion provided significant improvement in both {"}off periods{"} and dyskinesia. Results of plasma pharmacokinetic studies demonstrated that compared with oral administration, continuous levodopa infusion was associated with a significant increase in the levodopa area under the curve and avoided the low plasma trough levels seen with oral drug administration. Conclusions: This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD. Pharmacokinetic studies demonstrate that reduced motor complications are associated with avoiding low plasma levodopa trough levels and are not adversely affected by relatively high plasma levodopa concentrations. We propose that if levodopa/ carbidopa could be administered orally in a manner that mirrors the pharmacokinetic pattern of the infusion, it might lead to a similar reduction in motor complications.",
author = "Fabrizio Stocchi and Laura Vacca and Stefano Ruggieri and Olanow, {C. Warren}",
year = "2005",
month = "6",
doi = "10.1001/archneur.62.6.905",
language = "English",
volume = "62",
pages = "905--910",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease

T2 - A clinical and pharmacokinetic study

AU - Stocchi, Fabrizio

AU - Vacca, Laura

AU - Ruggieri, Stefano

AU - Olanow, C. Warren

PY - 2005/6

Y1 - 2005/6

N2 - Background: Levodopa-related motor complications can be an important source of disability for patients with advanced Parkinson disease. Current evidence suggests that these motor complications are related to the relatively short half-life of levodopa and its potential to induce pulsatile stimulation of striatal dopamine receptors. Motor complications can be diminished with a continuous infusion of levodopa. Objective: To investigate the specific pharmacokinetic changes associated with the benefits of levodopa infusion. Design: We performed an open-label study in 6 patients with Parkinson disease who experienced severe motor complications while receiving standard oral formulations of levodopa/carbidopa. Patients were subsequently treated for 6 months with continuous daytime intraintestinal infusions of levodopa methyl ester. Levodopa pharmacokinetic studies were performed at baseline and 6 months in 3 of these patients. Results: Compared with treatment with intermittent doses of a standard oral formulation of levodopa, continuous infusion provided significant improvement in both "off periods" and dyskinesia. Results of plasma pharmacokinetic studies demonstrated that compared with oral administration, continuous levodopa infusion was associated with a significant increase in the levodopa area under the curve and avoided the low plasma trough levels seen with oral drug administration. Conclusions: This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD. Pharmacokinetic studies demonstrate that reduced motor complications are associated with avoiding low plasma levodopa trough levels and are not adversely affected by relatively high plasma levodopa concentrations. We propose that if levodopa/ carbidopa could be administered orally in a manner that mirrors the pharmacokinetic pattern of the infusion, it might lead to a similar reduction in motor complications.

AB - Background: Levodopa-related motor complications can be an important source of disability for patients with advanced Parkinson disease. Current evidence suggests that these motor complications are related to the relatively short half-life of levodopa and its potential to induce pulsatile stimulation of striatal dopamine receptors. Motor complications can be diminished with a continuous infusion of levodopa. Objective: To investigate the specific pharmacokinetic changes associated with the benefits of levodopa infusion. Design: We performed an open-label study in 6 patients with Parkinson disease who experienced severe motor complications while receiving standard oral formulations of levodopa/carbidopa. Patients were subsequently treated for 6 months with continuous daytime intraintestinal infusions of levodopa methyl ester. Levodopa pharmacokinetic studies were performed at baseline and 6 months in 3 of these patients. Results: Compared with treatment with intermittent doses of a standard oral formulation of levodopa, continuous infusion provided significant improvement in both "off periods" and dyskinesia. Results of plasma pharmacokinetic studies demonstrated that compared with oral administration, continuous levodopa infusion was associated with a significant increase in the levodopa area under the curve and avoided the low plasma trough levels seen with oral drug administration. Conclusions: This study confirms that a continuous levodopa infusion is associated with reduced motor complications compared with the standard oral formulation of the drug in patients with advanced PD. Pharmacokinetic studies demonstrate that reduced motor complications are associated with avoiding low plasma levodopa trough levels and are not adversely affected by relatively high plasma levodopa concentrations. We propose that if levodopa/ carbidopa could be administered orally in a manner that mirrors the pharmacokinetic pattern of the infusion, it might lead to a similar reduction in motor complications.

UR - http://www.scopus.com/inward/record.url?scp=20844454214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844454214&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.6.905

DO - 10.1001/archneur.62.6.905

M3 - Article

C2 - 15956161

AN - SCOPUS:20844454214

VL - 62

SP - 905

EP - 910

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 6

ER -